Pharmacist Sebastian Franck

Sebastian Franck

Institute of Pharmacy

Field of Activity

Clinical Pharmacy & Biochemistry

Address Freie Universität Berlin

Kelchstr. 31
Room 237
12169 Berlin
Telephone 030-838 58132
Email sebastian.franck[at]fu-berlin.de

Curriculum vitae

 
 

Since 07/2016

PhD student at the Dept. of Clinical Pharmacy and Biochemistry
supervised by Prof. Dr. Charlotte Kloft

08/2015-02/2016

Pharmacist at the Gode Wind Apotheke, Hamburg

07/2015

Registered as Pharmacist

11/2014-04/2015

Pharmaceutical intern at the Dept. of Pharmaceutics, University
of Florida, Gainesville, Florida, USA

05/2014-11/2014

Pharmaceutical intern at the Gode Wind Apotheke, Hamburg

11/2013-04/2014

Pharmaceutical Intern at Merck KGaA, Research and Development,
Darmstadt

10/2009-09/2013

Studies of Pharmacy, Freie Universität Berlin

07/2008-07/2009

Voluntary Year of Social Service

06/2008

A level (Abitur), Bernhard-Riemann-Gymnasium, Scharnebeck

Focus of research

 

In the treatment of bacterial infections, the emergence of resistances is an increasing problem. This results in a more challenging antibacterial therapy and causes numerous cases of death worldwide. Bacterial resistance emerges in terms of different mechanisms and bacteria are adapting to new conditions consistently. Hence using antibiotics leads to an increasing selection of strains with reduced susceptibility.

 

Developing new antibiotics is one strategy that cannot tackle these challenges alone. In addition to measures of prevention, optimised diagnostics, an evidence-based and rational use of drugs, administration of drug combinations are promising alternatives to preserve their efficacy and deal with bacterial resistances. Combinations of different antibiotics are already used for the treatment of various infectious diseases, e.g. tuberculosis.

 

The objective of my PhD thesis in the context of the EU project ABIMMUNE of the “Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)” is to develop a non-traditional combination therapy for treatment of respiratory tract infections to minimise emergence of resistance and treatment failures. Particularly bacteria causing respiratory tract infections have a high risk for emerging resistances and are the most frequent causative pathogens for fatal infections.

Combinations of immunomodulatory drugs and disused and neglected antibiotics provide a novel approach to treat these infections. Stimulating the immune system can help to support the antibiotic drug and the human body to overcome an infection.

 

In the ABIMMUNE project, the influence of these combinations against pathogenic bacteria is investigated. In in vitro investigations for single drugs and combinations minimal inhibitory concentrations (MIC) are determined and time-kill behaviour is assessed. Simulations are performed with the obtained pharmacokinetic (PK) data as concentration-time profiles and pharmacodynamic (PD) data as resulting bacteria concentrations to characterise interactions and effects of the combinations. By linking these results to other human PK data, dosing strategies of synergistic drug combinations will be developed and analysed in animal models by partners of the project.

 

Finally, differences between in vitro and in vivo will be analysed using the obtained data, the animal models will be optimised and finally simulations for clinical studies will be performed to assess the efficacy of the therapy in a clinical setting.